Clinical trials: Immunocompromised
COVID 19, Influenza
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with…
- Conditions
- COVID 19, Influenza, Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus
- Trial name
- CO2I2 (NCT06599658)
- Testing
- Inactivated influenza vaccine (IIV) at baseline, COVID-19 Vaccines at a 3-month interval, Inactivated influenza vaccine at Month 1
- Where
- 3 sites in Canada
- Volunteers
- 660 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Candidiasis
Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units
This study will examine whether the anti-fungal drug caspofungin can prevent Candida infections in adult patients in intensive care units (ICUs).
- Trial name
- NCT00099775
- Testing
- Caspofungin
- Where
- United States
- Volunteers
- 1,200 people
- Sponsor
- National Cancer Institute (NCI)
Tuberculosis, HIV Infections
Identification of Cytokine Profiles and T Cell Subsets Among Immunosuppressed Patients at Risk of Developing Active Tuberculosis
The purpose of this study is to identify differences in TB specific immune responses among immunosuppressed patients latently infected with TB and patients with active TB.
- Conditions
- Tuberculosis, HIV Infections, Rheumatoid Arthritis
- Trial name
- NCT00285441
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Hvidovre University Hospital